LC-MS Method Detects GHRP-2 Metabolite in Urine Up to 20 Hours Post-Dose
Background
Doping with growth hormone releasing peptides (GHRPs) represents a comparably new and undetected form of cheating in sport. GHRPs are orally active small peptides that stimulate endogenous growth hormone (GH) production, making them attractive alternatives to injected recombinant GH. Critically, the established anti-doping test for exogenous GH fails entirely to flag GHRP misuse, leaving a significant detection gap. The metabolism of most GHRP candidates remains largely uncharacterised, meaning detection strategies must currently focus on intact parent peptides rather than well-defined urinary metabolite profiles — a challenge that demands sensitive, broad-coverage analytical methods.
Study Design
Researchers developed and validated a liquid chromatography–mass spectrometry (LC-MS) method for extracting and detecting eight GHRP candidates — GHRP-1, GHRP-2, GHRP-4, GHRP-5, GHRP-6, alexamorelin, ipamorelin, and hexarelin — from human urine. The known major metabolite of GHRP-2 (D-Ala-D-2-naphthylAla-L-Ala) and its stable isotope-labelled analogue were synthesised and incorporated into the assay. High-resolution, high-accuracy full-scan MS with higher collision energy dissociation (HCD) experiments enabled a non-targeted approach for retrospective metabolite discovery. Method validation covered specificity, precision, intermediate precision, recovery, LOD, linearity, ion suppression, and stability. Proof-of-principle was established by analysing excretion-study urine samples from a single oral 10 mg dose of GHRP-2 in one human subject.
Results
Validation demonstrated fit-for-purpose performance across all qualitative parameters. Precision and intermediate precision were both <20%, recovery ranged from 47% to 95% depending on analyte, and limits of detection spanned 0.2–1 ng/mL across the eight target peptides. Two stable isotope-labelled internal standards — deuterium-labelled GHRP-4 and the GHRP-2 metabolite — were used to support quantitative reliability. Ion suppression, linearity, and stability were all assessed and addressed within the validated framework.
In the single-subject oral excretion study, the GHRP-2 metabolite (D-Ala-D-2-naphthylAla-L-Ala) remained detectable for 20 hours after administration of 10 mg GHRP-2, while intact GHRP-2 parent drug was not observed in urine at any time point.
The non-targeted HCD full-scan acquisition strategy was designed to enable retrospective mining of raw data files for novel or unknown metabolites as structural information becomes available — a forward-looking capability given that the metabolism of most GHRP candidates remains uncharacterised.
Key Findings
- LOD range: 0.2–1 ng/mL across all eight GHRP targets in human urine
- Recovery: 47–95% depending on analyte; precision and intermediate precision both <20%
- GHRP-2 metabolite detectable for 20 h after a single 10 mg oral dose
- Intact GHRP-2 parent drug was not detected in urine at any post-dose time point
- Two stable isotope-labelled internal standards (deuterium-GHRP-4 and GHRP-2 metabolite) validated
Why It Matters
Anti-doping laboratories now have a validated, multi-analyte LC-MS protocol covering the eight most relevant GHRP candidates in a single urine assay, filling a critical gap left by GH immunoassays. The 20 h metabolite detection window for GHRP-2 provides actionable guidance on sampling timing relative to suspected administration. Athletes and clinical users should be aware that GHRP-2 metabolites — not the intact drug — are the primary urinary markers, meaning absence of the parent compound does not guarantee a clean sample. The non-targeted full-scan data architecture means stored historical samples could be retroactively screened as new metabolite data emerges, extending the effective detection reach without re-running subjects.
